

Form PTO-1449 (modified)

Atty. Docket No.

CLFR:167US

Serial No.

09/244,195

Office of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

George Barrie Kitto

Marry Susan Burnett

Filing Date:

February 4, 1999

Group:

1648

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	4,757,013	7/12/88	Inouye et al.	435	172.3	6/26/86

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 92/11028	7/9/92	WIPO			English
	B2	WO 96/11708	4/25/96	WIPO			English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Berggren et al., "HIV gp120-specific cell-mediated immune responses in mice after oral immunization with recombinant Salmonella," <i>J. Acquir. Immun. Defic. Syndr. Hum Retrovirol.</i> 10:489-495, 1995.
	C2	Bende and Johnston, "Update: search for an AIDS vaccine," <i>AIDS reader</i> September, 526-538, 2000.
	C3	Burnett et al., "Potential live vaccines for HIV," <i>Vaccine</i> , 19:735-742, 2000.
	C4	Burton and Moore, "Why do we not have an HIV vaccine and how can we make one?", <i>Nat. Med.</i> , 4(5):495-498, 1998.
	C5	Feinberg, and Moore, "AIDS vaccine models: challenging challenge viruses," <i>Nat. Med.</i> 8(3):207-210, 2002.
	C6	Ferns et al., "Monoclonal antibodies define linear and conformational epitopes of HIV-1 pol gene products," <i>AIDS Res. Human Retrovir.</i> , 7(3):307-313, 1991.
	C7	Francisco et al., "Transport and anchoring of beta-lactamase to the external surface of <i>Escherichia coli</i> ," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 89:2713-2717, 1992.
	C8	Georgiou et al., "Display of heterologous proteins on the surface of microorganisms: from the screening of combinatorial libraries to live recombinant vaccines," <i>Nature Biotech.</i> 15:29-34, 1997.

25529098.1

EXAMINER:

DATE CONSIDERED:

12/01/01

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

* Does not comply with 37 CFR 1.77(e).

P.E. JC56
MAY 27 2005
PATENT & TRADEMARK

Form PTO-1449 (modified)

Atty. Docket No.

CLFR:167US

Serial No.

09/244,195

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

George Barrie Kitto

Marry Susan Burnett

Filing Date:

February 4, 1999

Group:

1648

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C9	Haynes, "HIV vaccines: where we are and where we are going," <i>Lancet</i> 348:933-937, 1996.
	C10	Hinkula <i>et al.</i> , "Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes," <i>J. Virol.</i> 71(7):5528-5539, 1997.
	C11	Hoth <i>et al.</i> , "HIV vaccine development: a progress report," <i>Ann. Int. Med.</i> , 8(7):603-611, 1994.
	C12	Johnston, "The role of nonhuman primate models in AIDS vaccine development," <i>Mol. Med.</i> , 6:267-270, 2000.
	C13	Kent <i>et al.</i> , "Antagonism of vaccine-induced HIV-1-specific CD4+ T cells by primary HIV-1 infection: potential mechanism of vaccine failure," <i>J. Immunol.</i> 158:807-815, 1997.
	C14	Lerwin, "Progress in the development of an HIV_1 vaccine," <i>Science</i> 280:1875-1880, 1998.
	C15	Michel <i>et al.</i> , "Recombinant hepatitis B surface antigen as a carrier of human immunodeficiency virus epitopes," <i>Res. Virol.</i> 144:263-267, 1993.
	C16	Moore and Burton, "HIV-1 neutralizing antibodies: how full is the bottle?," <i>Nat. Med.</i> , 5(2):142-144, 1999.
	C17	Nathanson and Mathieson, "Biological considerations in the development of a human immunodeficiency virus vaccine," <i>J. Infect. Dis.</i> , 182:579-589, 2000.
	C18	O'Callaghan <i>et al.</i> , "High efficiency transformation of <i>Salmonella typhimurium</i> and <i>Salmonella typhi</i> by electroporation," <i>Mol. Gen. Genet.</i> , 223:156-158, 1990.
	C19	Richins <i>et al.</i> , "Biodegradation of organophosphorus pesticides by surface-expressed organophosphorus hydrolase," <i>Nat. Biotech.</i> , 15:984-987, 1997.
	C20	Silver and Gupta, "Turning poison eaters inside out," <i>Nat. Biotech.</i> , 15:953, 1997.
	C21	Stabel <i>et al.</i> , "Oral immunization of mice and swine with an attenuated <i>Salmonella choleraesuis</i> [delta cya-12 delta(crp-cdt)19] mutant containing a recombinant plasmid," <i>Infect. Immun.</i> , 61:610-618, 1993.
	C22	Stott and Almond, "Assessing animal models of AIDS," <i>Nat. Med.</i> 1(4):295-297, 1995.
	C23	Turner <i>et al.</i> , "Expression of <i>Chlamydia psittaci</i> - and human immunodeficiency virus-derived antigens on the cell surface of <i>Lactobacillus fermentum</i> BR11 as fusions to bspA," <i>Infect. Immune.</i> , 67:5486-5489, 1999.

25529098.1

EXAMINER:

DATE CONSIDERED:

12/07/06

EXAMINER: INITIAL & REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

* Does not comply with 37 CFR 1.97(e).

Form PTO-1449 (modified)

Atty. Docket No.

CLFR:167US

Serial No.

09/244,195

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

George Barrie Kitto

Marry Susan Burnett

Filing Date:

February 4, 1999

Group:

1648

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C24	Walker <i>et al.</i> , "HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals," <i>Science</i> , 240(4848):64-66, 1988.
	C25	Walker <i>et al.</i> , "Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 86(23):9514-9518, 1989.

25529098.1

EXAMINER:

DATE CONSIDERED:

12/07/04

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

* Does not comply with 37 CFR 1.97(e).